● Recruiting

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Condition: Non-Small Cell Lung Cancer (NSCLC) · Sponsor: Amgen

PhasePhase 3

Planned participants750

Who can joinAll sexes, 18 Years to 100 Years

Healthy volunteersNo

About this study

The primary objectives are to compare progression-free survival (PFS) and overall survival (OS) in participants who receive sotorasib with platinum doublet chemotherapy versus participants who receive pembrolizumab with platinum doublet chemotherapy.

This description comes directly from the study's public registry record.

Talk to the study team

Amgen Call Center · 866-572-6436 · medinfo@amgen.com

Always discuss trial participation with your own doctor first.

Locations (403)

Sansum Clinic	Santa Barbara, California, United States	Recruiting
Medical Oncology Hematology Consultants Helen F Graham Cancer Center	Newark, Delaware, United States	Recruiting
University of Illinois Chicago	Chicago, Illinois, United States	Recruiting
Illinois Cancer Specialists	Niles, Illinois, United States	Recruiting
Norton Cancer Institute - Brownsboro	Louisville, Kentucky, United States	Completed
Reliant Medical Group Inc	Worcester, Massachusetts, United States	Recruiting
University of New Mexico Cancer Center	Albuquerque, New Mexico, United States	Recruiting
Memorial Sloan Kettering Cancer Center	New York, New York, United States	Terminated
Messino Cancer Centers Asheville	Asheville, North Carolina, United States	Recruiting
Duke University Medical Center	Durham, North Carolina, United States	Recruiting
FirstHealth Cancer Center	Pinehurst, North Carolina, United States	Recruiting
Dayton Physician's Network	Dayton, Ohio, United States	Recruiting

+ 391 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05920356